Endpoints News
FDA approves Corcept’s Lifyorli for ovarian cancer months early
The FDA approved Corcept Therapeutics’ Lifyorli in combination with nab-paclitaxel for the treatment of three different kinds of cancer in patients who have received up to three prior lines of treatments.
The Wednesday approval came …